Oral tofacitinib for generalized Dowling-Degos disease with refractory pruritus: a case report

Oral tofacitinib for generalized Dowling-Degos disease with refractory pruritus: a case report

Aim To evaluate the efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in generalized Dowling-Degos disease (DDD) with refractory pruritus and to comparatively analyze its advantages and limitations versus existing therapies.Methods We report a 61-year-old male with a 20-year histor...

Full description

Saved in:
Bibliographic Details
Main Authors: Luan Yang, Ming Jing, Zhenqiang Ruan, Le Zhuang, Debao Yu, Jianfang Sun
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Dowling-Degos disease
Janus kinase inhibitor
tofacitinib
dermoscopic feature
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2025.2516716
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2025.2516716

Similar Items